 |
 |
 |
|
Pharmacokinetics of Dolutegravir in Subjects With Moderate Hepatic Impairment
|
|
|
Reported by Jules Levin
CROI 2012 March 5-8 Seattle WA
Ivy Song, Julie Borland, Paul Savina, Shuguang Chen, Parul Patel, Toshihiro Wajima, Amanda Peppercorn, Stephen Piscitelli
GlaxoSmithKline, Research Triangle Park, NC, United States, and Shionogi & Co., Ltd., Osaka, Japan






|
|
|
 |
 |
|
|